TACLONEX TOPICAL SUSPENSION Rx
Generic Name and Formulations:
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%.
LEO Pharma Inc.
Indications for TACLONEX TOPICAL SUSPENSION:
Plaque psoriasis of the scalp in patients 12–17yrs. Plaque psoriasis of the scalp and body in patients ≥18yrs.
Apply to affected areas once daily for up to 8 weeks; discontinue when control is achieved. 12–17yrs: max 60g/week. ≥18yrs: max 100g/week. Do not occlude.
Avoid use near eyes, on face, groin, or axillae, or if atrophy is present at treatment site. Discontinue if hypercalcemia or hypercalciuria develop; may resume once calcium metabolism has normalized. Discontinue or reduce dose or potency if HPA axis suppression, Cushing's syndrome, hyperglycemia, or irritation occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Avoid sun, UV light (eg, phototherapy). Allergic contact dermatitis. Pregnancy. Nursing mothers.
Vit. D3 derivative + topical steroid.
Systemic absorption potentiated by other corticosteroids.
Oint: pruritus, scaly rash. Susp: folliculitis, burning sensation of skin.
Oint—60g, 100g; Susp—60g, 2x60g